Cabotegravir is a long-acting antiretroviral medicine used as for HIV prevention in people vulnerable to infection. © Isabel Corthier

05 October 2022

South Africa can and must demand better deals for drug clinical trials — lives depend on it

Clinical trials are a fundamental pillar of the research and development (R&D) process for any new drug or vaccine. South Africa’s involvement in several recent trials has been essential to international pharmaceutical companies’ global rollouts — but, argue Candice Sehoma and Lebohang Kobola, the government needs to stand firm and negotiate more shrewdly for access to these medicines.

VACCINES

Latest news

Press release |

14 September 2022

MSF warns that supply delays of critical TB test will cost lives

Technical brief |

13 September 2022

Africa-South Korea Roundtable: Working Together on Local Production of Diagnostics

Press release |

31 August 2022

MSF responds to agreement between Aspen Pharmacare and Serum Institute of India to produce four routine vaccines in South Africa

Statement |

23 August 2022

Principles for Access to Multi-disease Molecular Diagnostics

Technical brief |

01 August 2022

The importance of pre-grant patent oppositions in increasing access to medical products

Press release |

28 July 2022

Following WHO recommendation, access to new game-changing HIV prevention drug needs to be accelerated

Video |

28 July 2022

#ShareTheTech - why pharma must share the mRNA vaccine technology

Issue brief |

25 July 2022

Cabotegravir: What are we waiting for?

Letter |

19 July 2022

CSO letter to ViiV calling for access to HIV PrEP drug CAB-LA

Press release |

24 June 2022

MSF responds to BioNTech announcement that it will set up first “BioNTainers” by end of 2022

Press release |

23 June 2022

MSF warns that reduced funding for Neglected Tropical Diseases could be devastating

Press release |

17 June 2022

Inability to agree a real pandemic intellectual property Waiver at WTO is a devastating global failure for people the world over

Work you can support right now!

Share mRNA tech - Solidarity, global public good, sharing is caring

Prepare for the Future

Currently, many low- and middle-income countries (LMICs) are almost entirely dependent on imports and donations of COVID and other vaccines, contributing to vaccine inequity.

If mRNA vaccine technology from Moderna, BioNTech and Pfizer were shared, manufacturers in low- and middle-income countries could produce vaccines for global pandemic preparedness, as well as diseases of concern such as HIV, TB and malaria.

How you can support